Download PDF
Digestive Disease Interventions 2021; 05(02): 090-092
DOI: 10.1055/s-0041-1729944
Review Article

Radioembolization for Metastatic Colorectal Cancer

David Guez
1   Division of Interventional Radiology, Department of Radiology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts
,
Patrick D. Sutphin 
2   Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
,
Suvranu Ganguli 
1   Division of Interventional Radiology, Department of Radiology, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The liver is the most common site of metastatic disease in colorectal cancer, and, in the setting of liver-dominant disease, a chief contributor to mortality. Chemotherapy is the backbone of treatment for metastatic colorectal cancer; however, the duration of response is limited and resistance to therapy inevitably develops. Radioembolization represents a targeted treatment to the liver which has been studied in first-line, second-line, and in salvage treatment. Therapeutic rationale, outcomes, and prognostic indicators are presented in this systematic review article.

Keywords

radioembolization - colorectal cancer - transarterial therapy


Publication History

Received: 07 January 2021

Accepted: 01 April 2021

Article published online:
17 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep 2016; 6: 29765
    CrossrefPubMedGoogle Scholar
  • 2 Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol 2014; 21 (02) 501-506
    CrossrefPubMedGoogle Scholar
  • 3 Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141 (05) 586-589
    CrossrefPubMedGoogle Scholar
  • 4 Kuipers EJ, Grady WM, Lieberman D. et al. Colorectal cancer. Nat Rev Dis Primers 2015; 1: 15065
    CrossrefPubMedGoogle Scholar
  • 5 Siegel RL, Miller KD, Goding Sauer A. et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70 (03) 145-164
    CrossrefPubMedGoogle Scholar
  • 6 Wong SL, Mangu PB, Choti MA. et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28 (03) 493-508
    CrossrefPubMedGoogle Scholar
  • 7 Wright RD. The blood supply of newly developed epithelial tissue in the liver. J Pathol Bacteriol 1937; 45 (02) 405-414
    CrossrefPubMedGoogle Scholar
  • 8 Bierman HR, Byron Jr RL, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 1951; 12 (01) 107-131
    PubMedGoogle Scholar
  • 9 Hickey R, Lewandowski RJ, Prudhomme T. et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med 2016; 57 (05) 665-671
    CrossrefPubMedGoogle Scholar
  • 10 Abbott AM, Kim R, Hoffe SE. et al. Outcomes of TheraSphere radioembolization for colorectal metastases. Clin Colorectal Cancer 2015; 14 (03) 146-153
    CrossrefPubMedGoogle Scholar
  • 11 Jakobs TF, Paprottka KJ, Raeßler F. et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol 2017; 27 (01) 113-119
    CrossrefPubMedGoogle Scholar
  • 12 Kennedy A, Cohn M, Coldwell DM. et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol 2017; 8 (04) 614-624
    CrossrefPubMedGoogle Scholar
  • 13 Kalva SP, Rana RS, Liu R. et al. Yttrium-90 radioembolization as salvage therapy for liver metastases from colorectal cancer. Am J Clin Oncol 2017; 40 (03) 288-293
    CrossrefPubMedGoogle Scholar
  • 14 Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med 2017; 58 (Suppl. 02) 104S-111S
    CrossrefPubMedGoogle Scholar
  • 15 Narsinh KH, Van Buskirk M, Kennedy AS. et al. Hepatopulmonary shunting: a prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with 90Y radioembolization. Radiology 2017; 282 (01) 281-288
    CrossrefPubMedGoogle Scholar
  • 16 van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731
    CrossrefPubMedGoogle Scholar
  • 17 Wasan HS, Gibbs P, Sharma NK. et al; FOXFIRE Trial Investigators, SIRFLOX Trial Investigators, FOXFIRE-Global Trial Investigators. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18 (09) 1159-1171
    CrossrefPubMedGoogle Scholar
  • 18 Ali R, Gabr A, Mora R, Riaz A, Lewandowski R. Role of Y-90 radioembolization in hepatic metastatic colorectal carcinoma. In: Correia M, Choti M, Rocha F, Wakabayashi G. eds. Colorectal Cancer Liver Metastases. Cham: Springer; 2020
    Google Scholar
  • 19 Chauhan N, Mulcahy MF, Salem R. et al. TheraSphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: protocol for the EPOCH Phase 3 randomized clinical trial. JMIR Res Protoc 2019; 8 (01) e11545
    CrossrefPubMedGoogle Scholar
  • 20 Lewandowski RJ, Thurston KG, Goin JE. et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16 (12) 1641-1651
    CrossrefPubMedGoogle Scholar
  • 21 Kennedy AS, Coldwell D, Nutting C. et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65 (02) 412-425
    CrossrefPubMedGoogle Scholar
  • 22 Jakobs TF, Hoffmann RT, Dehm K. et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19 (08) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 23 Mulcahy MF, Lewandowski RJ, Ibrahim SM. et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009; 115 (09) 1849-1858
    CrossrefPubMedGoogle Scholar
  • 24 Cianni R, Urigo C, Notarianni E. et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009; 32 (06) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 25 Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol 2010; 21 (10) 1521-1526
    CrossrefPubMedGoogle Scholar